Stock Market News

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year

Jun 12, 2025 - 18:48
 0
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
Read More

Tags:

Previous Article

Aircraft startup JetZero to invest $4.7 billion over a decade in North Carolina HQ

Next Article

JetZero to invest $4.7 billion in North Carolina

Related Posts

CVC Capital Partners Is oversold, says Morgan Stanley

CVC Capital Partners Is oversold, says Morgan Stanley

May 16, 2025  0

Elon Musk says SpaceX won’t decommission Dragon spacecraft

Jun 6, 2025  0

BAE Systems receives "buy" rating from BofA amid shifting global defense

BAE Systems receives "buy" rating from BofA amid shifti...

Jun 10, 2025  0